<html>
<head>PUBMED IDs for CD9P-1</head>
<body bgcolor='#C5F0F2'><h1>CD9P-1</h1><a href='https://pubmed.ncbi.nlm.nih.gov/11278880/'>The major CD9 and CD81 molecular partner. Identification and characterization of the complexes.</a> March 30  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/16380109/'>Reduced fertility of female mice lacking CD81.</a> December 29  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/16380105/'>Influence of T-786C polymorphism on the promoter activity of eNOS.</a> December 29  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/17407154/'>The transferrin receptor and the tetraspanin web molecules CD9, CD81, and CD9P-1 are differentially sorted into exosomes after TPA treatment of K562 cells.</a> April 5  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/20574531/'>The tetraspanins CD9 and CD81 regulate CD9P1-induced effects on cell migration.</a> November 4  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/20574529/'>The potential involvement of E-cadherin and beta-catenins in meningioma.</a> November 4  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/20574527/'>Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.</a> November 4  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21206492/'>CD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growth.</a> March 22  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21863033/'>A truncated form of CD9-partner 1 (CD9P-1), GS-168AT2, potently inhibits in vivo tumour-induced angiogenesis and tumour growth.</a> December 13  2011<br></body></html>
